Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 1.00 |
| ▸ | METAP2 | P50579 | 11/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.65 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.62 |
| ▸ | METAP1 | P53582 | 1/20 | 0.61 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoxycarbonyl Group SCHEMBL28826892 | 0.79 | IDO1 (0.63) | IDO1METAP2KEAP1SIRT3METAP1 | |
| SCHEMBL8221447 | 0.79 | METAP2 (1.00) | IDO1METAP2KEAP1SIRT3METAP1 | |
| SCHEMBL8664138 | 0.77 | METAP2 (0.95) | IDO1METAP2KEAP1SIRT3METAP1 | |
| SCHEMBL29539786 | 0.77 | METAP2 (1.00) | IDO1METAP2KEAP1SIRT3METAP1 | |
| SCHEMBL28058540 | 0.77 | METAP2 (1.00) | IDO1METAP2KEAP1SIRT3METAP1 | |
| SCHEMBL28070596 | 0.76 | METAP2 (1.00) | IDO1METAP2KEAP1SIRT3METAP1 | |
| SCHEMBL104083 | 0.76 | METAP2 (0.64) | IDO1METAP2KEAP1SIRT3METAP1 | |
| SCHEMBL29626826 | 0.76 | METAP2 (1.00) | IDO1METAP2KEAP1SIRT3METAP1 | |
| SCHEMBL28033548 | 0.76 | METAP2 (0.64) | IDO1METAP2KEAP1SIRT3METAP1 | |
| SCHEMBL1030506 | 0.76 | METAP2 (0.63) | IDO1METAP2KEAP1SIRT3METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245667-A1 | MATERIALS AND METHODS USEFUL TO INDUCE CANCER CELL DEATH VIA METHUOSIS OR AUTOPHAGY OR A COMBINATION THEREOF | THE UNIVERSITY OF TOLEDO (US) | 2024-07-25 | — | — | US | claimed |
| US-20220370430-A1 | MATERIALS AND METHODS USEFUL TO INDUCE CANCER CELL DEATH VIA METHUOSIS OR AUTOPHAGY OR A COMBINATION THEREOF | THE UNIVERSITY OF TOLEDO (US) | 2022-11-24 | — | — | US | claimed |
| US-20200297709-A1 | MATERIALS AND METHODS USEFUL TO INDUCE CANCER CELL DEATH VIA METHUOSIS OR AUTOPHAGY OR A COMBINATION THEREOF | THE UNIVERSITY OF TOLEDO (US) | 2020-09-24 | — | — | US | disclosed |
| CN-105541796-A | Synthetic method of NH-1,2,3-triazole bipyridine compounds | WUHAN INST TECHNOLOGY | 2016-05-04 | — | — | CN | disclosed |
| EP-1313751-B1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| CN-1234718-C | New macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-01-04 | — | — | CN | disclosed |
| US-6740642-B2 | ACTIVE AGAINST GRAM POSITIVE PATHOGENS SUCH AS STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, GRAM NEGATIVE STRAINS SUCH AS HAEMOPHILUS INFLUENZAE; IMPROVED STABILITY | BASILEA PARMACEUTICA AG (CH) | 2004-05-25 | — | — | US | disclosed |
| CN-1464880-A | New macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-12-31 | — | — | CN | disclosed |
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
| EP-1313751-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016380-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297709-A1 | MATERIALS AND METHODS USEFUL TO INDUCE CANCER CELL DEATH VIA METHUOSIS OR AUTOPHAGY OR A COMBINATION THEREOF | BECN1, ATG7, CASP3 | IDO1 2244/4885METAP2 1196/4885KEAP1 484/4885 |
| US-20240245667-A1 | MATERIALS AND METHODS USEFUL TO INDUCE CANCER CELL DEATH VIA METHUOSIS OR AUTOPHAGY OR A COMBINATION THEREOF | BECN1, ATG7, CASP3 | IDO1 2244/4885METAP2 1196/4885KEAP1 484/4885 |
| US-20220370430-A1 | MATERIALS AND METHODS USEFUL TO INDUCE CANCER CELL DEATH VIA METHUOSIS OR AUTOPHAGY OR A COMBINATION THEREOF | BECN1, ATG7, CASP3 | IDO1 2244/4885METAP2 1196/4885KEAP1 484/4885 |
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | IDO1 3686/4885METAP2 2409/4885KEAP1 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.